Rapport Therapeutics Prepares for Major Epilepsy Conferences
![Rapport Therapeutics Prepares for Major Epilepsy Conferences](https://investorshangout.com/images/blog/ihnews-Rapport%20Therapeutics%20Prepares%20for%20Major%20Epilepsy%20Conferences.jpg)
Rapport Therapeutics Gears Up for Impactful Epilepsy Conferences
Rapport Therapeutics, Inc. (Nasdaq: RAPP), a biotechnology company at the forefront of developing innovative therapies for central nervous system (CNS) disorders, is making waves in the medical community as it prepares to present at two significant epilepsy conferences. The company aims to showcase its groundbreaking research and clinical developments that could transform the treatment landscape for patients dealing with epilepsy.
Upcoming Conference Details
The first event is the 15th Annual European Epilepsy Congress (EEC) taking place in Rome. Rapport will present a novel design for a Phase 2a proof-of-concept trial for its leading product candidate, RAP-219. This innovative approach aims to help patients living with drug-resistant focal epilepsy.
The second venue, the 2024 Epilepsy Foundation Pipeline Conference, will feature a detailed presentation on the underlying mechanisms of RAP-219 combined with insights from the Phase 2a trial. These presentations reflect Rapport's commitment to advancing treatment options for challenging CNS conditions.
Key Presentation Information
At the EEC, Rapport's presentation, titled "Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219," will focus on the implications of their findings. Scheduled for Sunday, September 8th, 2024, at 1:30 p.m. CEST, the session will be led by William Motley, M.D., who serves as the Senior Director of Clinical Development.
The Pipeline Conference will also feature notable insights into RAP-219. Arnold Gammaitoni, Pharm.D., Senior Vice President of Medical Affairs, will present on September 26th, showcasing how this candidate functions as a potent negative modulator of the AMPA receptor associated protein. Each presentation reflects the company's dedication to concentrating on patient-centered neurological treatments.
About RAP-219 and the Company
RAP-219 represents a significant advancement in treating CNS disorders with its precision-targeted approach that focuses on specific brain regions. This clinical-stage candidate is not only aimed at managing epilepsy but is also being investigated for potential applications in peripheral neuropathic pain and bipolar disorder. Rapport Therapeutics is committed to pioneering neurological therapies that address key limitations faced by conventional approaches.
Founded on the discovery of receptor associated proteins (RAPs) in the brain, Rapport’s innovative RAP technology platform supports the development of targeted solutions, ensuring high specificity and efficacy in treatment. The company also maintains a robust pipeline of preclinical and late-stage discovery programs targeting various CNS-related conditions, including chronic pain and hearing disorders.
Contact Information
For further details or inquiries, you can reach Julie DiCarlo, Head of Communications & IR at Rapport Therapeutics, by emailing jdicarlo@rapportrx.com.
Frequently Asked Questions
What is the focus of Rapport Therapeutics?
Rapport Therapeutics focuses on discovering and developing small molecule medicines for CNS disorders.
What is RAP-219?
RAP-219 is a candidate in clinical trials aimed at treating drug-resistant focal epilepsy and other CNS disorders.
When and where will the presentations take place?
The presentations are scheduled for the 15th European Epilepsy Congress in Rome and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta.
Who are the presenters for the conferences?
The presenters include William Motley, M.D., and Arnold Gammaitoni, Pharm.D., representing Rapport Therapeutics.
How can I learn more about Rapport's research?
Details of the presentations and additional information can be found on Rapport Therapeutics' website, under the Publications section after the conferences.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Insights from CNBC's 'Final Trades' Featuring Major Stocks
- Top Financial Stocks to Consider for High Dividend Returns
- Verizon's Bold Move: Acquiring Frontier for Growth
- Understanding Short Interest Trends for Healthpeak Properties
- PCB Financial Expands Deadline for Election Form Submissions
- Transforming Compliance: Zanko ComplianceAssist by Spring Labs
- Insights on AUGA Group's Financial Performance for 2024
- Shell plc Launches Comprehensive Exchange Offers for USD Notes
- Innovations for Women's Health: A Coalition for Change
- Actuate Therapeutics to Showcase Innovations at Key Conference
Recent Articles
- Applied Digital Secures $160 Million, Shares Surge by 50%
- Understanding Super Micro's Stock Decline and Future Potential
- Insider Sales Insights: Nvidia, Western Digital and Others
- Discover AutoZone's Recent Power Inflow Impact on Stocks
- Navigating Market Volatility: Insights on U.S. and India Stocks
- Insights from CNBC's 'Final Trades' Featuring Major Stocks
- Top Oversold Consumer Staples Stocks Worth Considering Now
- Nvidia Stock Faces Challenges Amid Market Volatility
- Top Financial Stocks to Consider for High Dividend Returns
- Verizon's Bold Move: Acquiring Frontier for Growth
- Understanding Enovix's Short Interest Trends and Insights
- Understanding Short Interest Trends for Healthpeak Properties
- Insights into Equinix's Short Interest Trends and Implications
- PCB Financial Expands Deadline for Election Form Submissions
- P2P Group Strengthens Leadership with Expert Advisory Board
- StealthGas Inc. Achieves Record Results in Latest Financials
- Northrop Grumman's Upcoming Presence at Morgan Stanley Event
- Freight Technologies Shows Growth with Notable Product Advancements
- Exploring XHANCE's Impact on Chronic Sinus Issues
- Transforming Compliance: Zanko ComplianceAssist by Spring Labs
- Insights on AUGA Group's Financial Performance for 2024
- ChannelEngine Empowers Brands to Recover Lost Amazon Revenue
- Rivian CEO to Speak at Key Finance Conference
- Discover the Revolutionary Volumizing Tinted Brow Gel from ABH
- Shell plc Launches Comprehensive Exchange Offers for USD Notes
- Revolutionizing Talent Acquisition with AI-Driven Solutions
- Clip Money Inc. Welcomes New Leadership to its Board
- ILGM Unveils Exclusive Seed Collection in Collaboration
- StealthGas Inc. Achieves Record Q2 2024 Results with Growth
- Angel Kids AI Raises $1.1M in Continued Seed Financing
- Innovations for Women's Health: A Coalition for Change
- Republic Services Earns Eighth Year of Great Workplace Honor
- Elevate Your Skincare with HA Intensifier Multi-Glycan
- First Connect and Root Enhance Insurance Agent Experience
- Actuate Therapeutics to Showcase Innovations at Key Conference
- Kait Dinunzio Joins Pyxis Advisory Group as Managing Director
- Blenders Eyewear Unveils Special Sunglasses for SDSU Players
- BDHEA Secures $1.5M Grant to Enhance Health Equity Efforts
- HanaByte's New Role as a Trusted Cloud Consultant
- New Research Highlights Improved Chemotherapy Tolerability
- Phagenesis Welcomes Chad Hoskins as New CEO to Drive Growth
- NetDiligence Launches Innovative Career Pathways Initiative
- EisnerAmper Expands by Welcoming Tighe, Kress & Orr Partners
- BNY's Acquisition of Archer Enhances Wealth Management Services
- US Signal Expands Leadership Team with New Executive Appointments
- S&P 500 Futures Recover Slightly Amid Jobless Claims Report
- Nordstrom's Strategic Shift: Exploring New Horizons
- Tadawul All Share Index Sees Slight Decline Amid Mixed Trades
- Disney Data Leak: Insights into Financial Strategies and Risks
- Blackstone Secures A$5.5 Billion Loan for AirTrunk Purchase